Editor’s Note: This is the second of a two-part series examining reverse-payment settlements in pharmaceutical patent litigation. The first part can be found here.
The U.S. Federal Trade Commission’s fight to eradicate “pay-for-delay” settlements between drug companies in patent disputes has drawn a local company into its sights and spilled over into Washington as another company fights an FTC subpoena in the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
